| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
17,001 |
14,996 |
$7.10M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
19,669 |
17,055 |
$5.05M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
8,316 |
7,297 |
$4.67M |
| G0378 |
Hospital observation service, per hour |
4,641 |
3,350 |
$3.72M |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
23,391 |
19,465 |
$2.49M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,484 |
2,209 |
$433K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,636 |
2,381 |
$379K |
| 80053 |
Comprehensive metabolic panel |
18,036 |
14,716 |
$355K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
24,391 |
18,342 |
$352K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,121 |
2,731 |
$324K |
| 71046 |
Radiologic examination, chest; 2 views |
4,942 |
4,489 |
$302K |
| 84484 |
|
8,015 |
6,155 |
$251K |
| 71045 |
Radiologic examination, chest; single view |
6,638 |
5,645 |
$221K |
| 70450 |
Computed tomography, head or brain; without contrast material |
5,239 |
4,716 |
$195K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,486 |
1,365 |
$172K |
| 59025 |
Fetal non-stress test |
254 |
217 |
$156K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
365 |
329 |
$152K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,933 |
1,724 |
$147K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,897 |
4,079 |
$140K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,340 |
1,234 |
$123K |
| 76801 |
|
341 |
296 |
$118K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
1,454 |
1,335 |
$102K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
6,989 |
5,082 |
$99K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,219 |
1,148 |
$98K |
| 73562 |
|
911 |
810 |
$98K |
| 81001 |
|
7,627 |
6,880 |
$97K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,340 |
1,985 |
$89K |
| 83605 |
|
3,510 |
2,827 |
$88K |
| 84702 |
|
1,736 |
1,478 |
$88K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,130 |
1,069 |
$88K |
| 80320 |
|
3,059 |
2,717 |
$80K |
| 84703 |
|
3,994 |
3,611 |
$75K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
791 |
706 |
$73K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
1,374 |
1,296 |
$73K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
777 |
697 |
$73K |
| 73130 |
|
754 |
677 |
$72K |
| 85730 |
|
4,179 |
3,700 |
$65K |
| 86803 |
|
1,351 |
1,273 |
$62K |
| 83690 |
|
5,314 |
4,691 |
$61K |
| 83735 |
|
8,708 |
6,068 |
$60K |
| 73610 |
|
601 |
526 |
$53K |
| 86850 |
|
2,550 |
2,236 |
$51K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
437 |
390 |
$51K |
| 87430 |
|
858 |
797 |
$47K |
| 83880 |
|
1,954 |
1,692 |
$47K |
| 73630 |
|
568 |
506 |
$47K |
| 73030 |
|
662 |
586 |
$46K |
| 82962 |
|
3,705 |
2,356 |
$45K |
| 85610 |
|
4,716 |
4,089 |
$42K |
| 70486 |
|
696 |
628 |
$38K |
| 81025 |
|
1,449 |
1,319 |
$36K |
| 81003 |
|
5,753 |
5,034 |
$36K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
162 |
151 |
$36K |
| 93971 |
|
146 |
132 |
$35K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
91 |
83 |
$35K |
| 87070 |
|
575 |
535 |
$32K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
123 |
112 |
$30K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,544 |
1,350 |
$26K |
| 86901 |
|
2,815 |
2,489 |
$25K |
| 85379 |
|
839 |
724 |
$25K |
| 72126 |
|
219 |
189 |
$23K |
| 93970 |
|
87 |
76 |
$23K |
| 76830 |
Ultrasound, transvaginal |
57 |
52 |
$21K |
| 90715 |
|
225 |
201 |
$19K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
410 |
383 |
$18K |
| 86900 |
|
2,650 |
2,331 |
$18K |
| 87210 |
|
1,062 |
967 |
$17K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
336 |
303 |
$16K |
| 72131 |
|
230 |
217 |
$15K |
| 82550 |
|
1,930 |
1,618 |
$15K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,814 |
2,331 |
$14K |
| A4606 |
Oxygen probe for use with oximeter device, replacement |
702 |
608 |
$12K |
| 72128 |
|
182 |
173 |
$12K |
| 73110 |
|
120 |
106 |
$11K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
45 |
38 |
$11K |
| 80061 |
Lipid panel |
639 |
553 |
$10K |
| 81015 |
|
1,212 |
992 |
$10K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
668 |
578 |
$10K |
| 72100 |
|
100 |
96 |
$9K |
| 87040 |
|
238 |
219 |
$9K |
| 84100 |
|
3,080 |
1,855 |
$9K |
| 73590 |
|
112 |
100 |
$9K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,361 |
1,920 |
$8K |
| 72170 |
|
89 |
78 |
$8K |
| 87081 |
|
162 |
147 |
$8K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
2,089 |
1,568 |
$7K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
233 |
208 |
$7K |
| 73502 |
|
76 |
70 |
$6K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
160 |
97 |
$6K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,262 |
1,078 |
$5K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,579 |
2,977 |
$5K |
| 97161 |
|
29 |
26 |
$5K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,118 |
703 |
$4K |
| A4649 |
Surgical supply; miscellaneous |
677 |
590 |
$4K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
12 |
12 |
$4K |
| 72132 |
|
44 |
37 |
$3K |
| J3490 |
Unclassified drugs |
231 |
189 |
$3K |
| 80329 |
|
137 |
117 |
$3K |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,248 |
605 |
$2K |
| 72129 |
|
32 |
25 |
$2K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
182 |
150 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
435 |
337 |
$2K |
| 73090 |
|
25 |
24 |
$2K |
| 94644 |
|
87 |
85 |
$2K |
| 97165 |
|
14 |
14 |
$2K |
| 85384 |
|
70 |
66 |
$2K |
| 85032 |
|
106 |
85 |
$2K |
| 82553 |
|
104 |
93 |
$1K |
| 73552 |
|
13 |
12 |
$1K |
| A9270 |
Non-covered item or service |
6,139 |
4,113 |
$1K |
| 82150 |
|
56 |
53 |
$958.07 |
| 80076 |
|
78 |
69 |
$878.38 |
| 87186 |
|
90 |
79 |
$821.69 |
| 85027 |
|
168 |
123 |
$719.61 |
| 94760 |
|
135 |
85 |
$675.52 |
| 74018 |
|
16 |
12 |
$391.83 |
| 71250 |
|
29 |
28 |
$343.29 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
373 |
338 |
$338.41 |
| 94010 |
|
12 |
12 |
$289.93 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
124 |
80 |
$283.07 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
91 |
25 |
$262.98 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
151 |
130 |
$259.19 |
| J2704 |
Injection, propofol, 10 mg |
84 |
69 |
$198.35 |
| 94664 |
|
25 |
25 |
$166.66 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
227 |
208 |
$159.46 |
| 87077 |
|
74 |
66 |
$152.52 |
| 87205 |
|
13 |
12 |
$108.01 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
42 |
40 |
$91.17 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
113 |
104 |
$77.78 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
424 |
354 |
$76.67 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
20 |
14 |
$42.41 |
| 84132 |
|
12 |
12 |
$28.13 |
| J1630 |
Injection, haloperidol, up to 5 mg |
26 |
14 |
$21.61 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
23 |
15 |
$20.89 |
| 0270 |
|
563 |
462 |
$0.00 |
| 0250 |
|
128 |
68 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
14 |
12 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
686 |
476 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
31 |
12 |
$0.00 |